Completed PHASE1 INTERVENTIONAL 1-arm NCT02014337

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.

Sponsor: Corcept Therapeutics

Conditions Breast Cancer Carcinoma, Transitional Cell Non-small Cell Lung Cancer Ovarian Epithelial Cancer Recurrent Prostate Cancer Prostatic Neoplasms Sarcoma

Interventions Mifepristone and Eribulin in combination

Updated 8 times since 2017 Last updated: Jan 12, 2018 Started: Jan 31, 2014 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02014337, this PHASE1 trial focuses on Breast Cancer and Carcinoma, Transitional Cell and remains completed. Sponsored by Corcept Therapeutics, it has been updated 8 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

Sep 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corcept Therapeutics

Data source: Corcept Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Chicago, United States , Dallas, United States , Fairfax, United States , Kansas City, United States , Las Vegas, United States , Royal Oaks, United States , San Antonio, United States , Tampa, United States , Tucson, United States and 1 more location